Skip to main content
Caplight Logo









mbiomics GmbH

mbiomics GmbH

Private
MunichHealthcare & Life Scienceshttps://www.mbiomics.com/

Last Round

Series A

Apr 28, 2026

Total Funding Raised

$70.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

mbiomics GmbH is a biotechnology company that develops live bacterial therapeutics and microbiome-based diagnostic platforms for severe and chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

microbiome therapeuticslive biotherapeutic productsLBPbacterial consortiadrug discoveryoncology therapeuticsimmune checkpoint inhibitorAI drug discoveryin-silico designmicrobiome engineeringbiotech R&Dgut microbiomeprecision medicinesynthetic biologybioinformatics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

mbiomics GmbH Comparables

Compare mbiomics GmbH with similar companies based on industry and business-model similarity.

mbiomics GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Microbiotica
86%
Kanvas Biosciences
82%
Enterome
79%

mbiomics GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 28, 2026
Series AMar 23, 2023

Key People

Founding team and executive leadership

Kristin Torre Vinuesa

CFO, Managing Director

Executive Team

mbiomics GmbH Investors

Notable investors and investment history

mbiomics GmbH investors
InvestorRounds
MIG CapitalSeries A
Bayern KapitalSeries A
High-Tech GründerfondsSeries A
MIG FondsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    $35M round led by Bayern Kapital and MIG Fonds.

  • Apr 29, 2026

    Lead candidate MBX-116 preparing for clinical evaluation for advanced melanoma.

mbiomics GmbH Filings

Explore SEC and related filing metadata, where available.

mbiomics GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about mbiomics GmbH's valuation, stock price, and market status.

Is mbiomics GmbH a public or private company?

mbiomics GmbH is a private company.

What is the current stock price of mbiomics GmbH?

mbiomics GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is mbiomics GmbH worth (valuation)?

Valuation information for mbiomics GmbH is not publicly available.

Can I buy mbiomics GmbH stock?

mbiomics GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was mbiomics GmbH's last funding round?

mbiomics GmbH's most recent funding round was Series A on May 4, 2026.

Who are the main investors in mbiomics GmbH?

Key investors in mbiomics GmbH include MIG Capital, Bayern Kapital, MIG Fonds.

Will mbiomics GmbH IPO soon?

No public IPO plans have been announced for mbiomics GmbH.

How can I track mbiomics GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor mbiomics GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMunich
Employee Range33
Year Founded2020
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?